Comprehensive Stock Comparison
Compare Onconetix, Inc. (ONCO) vs Moderna, Inc. (MRNA) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | ONCO | 42.2% revenue growth vs MRNA's -53.3% |
| Quality / Margins | MRNA | -140.3% net margin vs ONCO's -40.2% |
| Stability / Safety | ONCO | Beta 1.22 vs MRNA's 1.25 |
| Dividends | ONCO | 100.0% yield; 1-year raise streak; MRNA pays no meaningful dividend |
| Momentum (1Y) | MRNA | +73.0% vs ONCO's -96.8% |
| Efficiency (ROA) | MRNA | -25.7% ROA vs ONCO's -249.7%, ROIC -27.0% vs -336.9% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Onconetix is a biotechnology company developing and commercializing therapies for various health conditions. It generates revenue primarily from its FDA-approved prostate treatment Entadfi, while also advancing a pipeline of vaccine candidates — including for pneumonia, universal flu, and norovirus — through licensing and development partnerships. The company's competitive advantage lies in its versatile nanoparticle vaccine platform licensed from Cincinnati Children's, which enables rapid development of vaccines for multiple infectious diseases.
Moderna is a biotechnology company that develops messenger RNA (mRNA) therapeutics and vaccines for infectious diseases, cancer, and other serious conditions. It generates revenue primarily from vaccine sales—notably its COVID-19 vaccine—with additional income from research collaborations and government grants. The company's key advantage is its proprietary mRNA technology platform, which enables rapid development of new vaccines and therapeutics compared to traditional methods.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
ONCO leads in 2 of 6 categories (Valuation Metrics, Analyst Outlook). MRNA leads in 2 (Profitability & Efficiency, Total Returns). 2 tied.
Financial Metrics (TTM)
MRNA is the larger business by revenue, generating $2.2B annually — 1814.9x ONCO's $1M. Profitability is closely matched — net margins range from -140.3% (MRNA) to -40.2% (ONCO). On growth, ONCO holds the edge at -25.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ONCOOnconetix, Inc. | MRNAModerna, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $1M | $2.2B |
| EBITDAEarnings before interest/tax | -$46M | -$3.3B |
| Net IncomeAfter-tax profit | -$49M | -$3.1B |
| Free Cash FlowCash after capex | -$8M | -$2.7B |
| Gross MarginGross profit ÷ Revenue | +85.4% | +11.9% |
| Operating MarginEBIT ÷ Revenue | -37.4% | -155.9% |
| Net MarginNet income ÷ Revenue | -40.2% | -140.3% |
| FCF MarginFCF ÷ Revenue | -6.1% | -119.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | -25.4% | -45.2% |
| EPS Growth (YoY)Latest quarter vs prior year | -113.3% | -16.6% |
Valuation Metrics
| Metric | ONCOOnconetix, Inc. | MRNAModerna, Inc. |
|---|---|---|
| Market CapShares × price | $8M | $20.9B |
| Enterprise ValueMkt cap + debt − cash | $17M | $19.8B |
| Trailing P/EPrice ÷ TTM EPS | -0.00x | -5.78x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 3.12x | 6.55x |
| Price / BookPrice ÷ Book value/share | 0.00x | 1.89x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
MRNA delivers a -33.4% return on equity — every $100 of shareholder capital generates $-33 in annual profit, vs $-15 for ONCO. MRNA carries lower financial leverage with a 0.07x debt-to-equity ratio, signaling a more conservative balance sheet compared to ONCO's 0.98x. On the Piotroski fundamental quality scale (0–9), MRNA scores 4/9 vs ONCO's 3/9, reflecting mixed financial health.
| Metric | ONCOOnconetix, Inc. | MRNAModerna, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -14.6% | -33.4% |
| ROA (TTM)Return on assets | -2.5% | -25.7% |
| ROICReturn on invested capital | -3.4% | -27.0% |
| ROCEReturn on capital employed | -140.8% | -28.9% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 |
| Debt / EquityFinancial leverage | 0.98x | 0.07x |
| Net DebtTotal debt minus cash | $9M | -$1.2B |
| Cash & Equiv.Liquid assets | $646,500 | $1.9B |
| Total DebtShort + long-term debt | $9M | $747M |
| Interest CoverageEBIT ÷ Interest expense | -49.30x | -393.13x |
Total Returns (with DRIP)
A $10,000 investment in MRNA five years ago would be worth $3,403 today (with dividends reinvested), compared to $0 for ONCO. Over the past 12 months, MRNA leads with a +73.0% total return vs ONCO's -96.8%. The 3-year compound annual growth rate (CAGR) favors MRNA at -27.2% vs ONCO's -94.5% — a key indicator of consistent wealth creation.
| Metric | ONCOOnconetix, Inc. | MRNAModerna, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | -58.4% | +73.6% |
| 1-Year ReturnPast 12 months | -96.8% | +73.0% |
| 3-Year ReturnCumulative with dividends | -100.0% | -61.4% |
| 5-Year ReturnCumulative with dividends | -100.0% | -66.0% |
| 10-Year ReturnCumulative with dividends | -100.0% | +188.0% |
| CAGR (3Y)Annualised 3-year return | -94.5% | -27.2% |
Risk & Volatility
ONCO is the less volatile stock with a 1.22 beta — it tends to amplify market swings less than MRNA's 1.25 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MRNA currently trades 97.0% from its 52-week high vs ONCO's 2.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ONCOOnconetix, Inc. | MRNAModerna, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.22x | 1.25x |
| 52-Week HighHighest price in past year | $25.50 | $55.20 |
| 52-Week LowLowest price in past year | $0.62 | $22.28 |
| % of 52W HighCurrent price vs 52-week peak | +2.6% | +97.0% |
| RSI (14)Momentum oscillator 0–100 | 33.5 | 71.6 |
| Avg Volume (50D)Average daily shares traded | 246K | 10.8M |
Analyst Outlook
ONCO is the only dividend payer here at 100.00% yield — a key consideration for income-focused portfolios.
| Metric | ONCOOnconetix, Inc. | MRNAModerna, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold |
| Price TargetConsensus 12-month target | — | $34.89 |
| # AnalystsCovering analysts | — | 27 |
| Dividend YieldAnnual dividend ÷ price | +100.0% | — |
| Dividend StreakConsecutive years of raises | 1 | 0 |
| Dividend / ShareAnnual DPS | $6.39 | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Feb 22 | Feb 26 | Change |
|---|---|---|---|
| Onconetix, Inc. (ONCO) | 100 | 0 | -100.0% |
| Moderna, Inc. (MRNA) | 100 | 28.46 | -71.5% |
Moderna, Inc. (MRNA) returned -66% over 5 years vs Onconetix, Inc. (ONCO)'s -100%.
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2024 | Change |
|---|---|---|---|
| Onconetix, Inc. (ONCO) | $0.00 | $3M | — |
| Moderna, Inc. (MRNA) | $108M | $3.2B | +2851.2% |
Moderna, Inc.'s revenue grew from $108M (2016) to $3.2B (2024) — a 52.7% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2024 | Change |
|---|---|---|---|
| Onconetix, Inc. (ONCO) | -639.9% | -23.3% | +96.4% |
| Moderna, Inc. (MRNA) | -199.5% | -111.3% | +44.2% |
Moderna, Inc.'s net margin went from -199% (2016) to -111% (2024).
Chart 4EPS Growth — 10 Years
| Stock | 2016 | 2024 | Change |
|---|---|---|---|
| Onconetix, Inc. (ONCO) | -0.07 | -1,823.25 | -2450504.8% |
| Moderna, Inc. (MRNA) | -3.79 | -9.27 | -144.6% |
Moderna, Inc.'s EPS grew from $-3.79 (2016) to $-9.27 (2024).
Chart 5Free Cash Flow — 5 Years
Onconetix, Inc. generated $-11M FCF in 2024 (-414% vs 2021). Moderna, Inc. generated $-4B FCF in 2024 (-130% vs 2021).
ONCO vs MRNA: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is ONCO or MRNA a better buy right now?
Analysts rate Moderna, Inc. (MRNA) a "Hold" — based on 27 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ONCO or MRNA?
Over the past 5 years, Moderna, Inc. (MRNA) delivered a total return of -66.0%, compared to -100.0% for Onconetix, Inc. (ONCO). A $10,000 investment in MRNA five years ago would be worth approximately $3K today (assuming dividends reinvested). Over 10 years, the gap is even starker: MRNA returned +188.0% versus ONCO's -100.0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ONCO or MRNA?
By beta (market sensitivity over 5 years), Onconetix, Inc. (ONCO) is the lower-risk stock at 1.22β versus Moderna, Inc.'s 1.25β — meaning MRNA is approximately 2% more volatile than ONCO relative to the S&P 500. On balance sheet safety, Moderna, Inc. (MRNA) carries a lower debt/equity ratio of 7% versus 98% for Onconetix, Inc. — giving it more financial flexibility in a downturn.
04Which has better profit margins — ONCO or MRNA?
Moderna, Inc. (MRNA) is the more profitable company, earning -111.3% net margin versus -23.3% for Onconetix, Inc. — meaning it keeps -111.3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MRNA leads at -123.3% versus -22.4% for ONCO. At the gross margin level — before operating expenses — MRNA leads at 54.2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — ONCO or MRNA?
In this comparison, ONCO (100.0% yield) pays a dividend. MRNA does not pay a meaningful dividend and should not be held primarily for income.
06Is ONCO or MRNA better for a retirement portfolio?
For long-horizon retirement investors, Onconetix, Inc. (ONCO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.22), 100.0% yield). Both have compounded well over 10 years (ONCO: -100.0%, MRNA: +188.0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between ONCO and MRNA?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: ONCO is a small-cap income-oriented stock; MRNA is a mid-cap quality compounder stock. ONCO pays a dividend while MRNA does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.